# AMT-253 in Patients With Advanced Solid Tumours

Source: https://onco.cc/trials/nct06209580/  
OnCo record `nct06209580` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AMT-253 for injection in melanoma, run by Multitude Therapeutics Inc., now recruiting.

## Summary

AMT-253 in Patients With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06209580 by Multitude Therapeutics Inc., with 96 participants planned, started 2024-01-31 and due to reach its primary completion in 2026-04-30. Interventions recorded: AMT-253 for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06209580
- Phase: 1/2
- Setting: Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors
- Sponsor: Multitude Therapeutics Inc.
- Enrolled: 96

## Sources

- ClinicalTrials.gov NCT06209580: https://clinicaltrials.gov/study/NCT06209580

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06209580.json